Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
ZD4190 demonstrates cytotoxic properties against cancerous cells [2].
|
---|---|
ln Vivo |
In mice, ZD4190 (100 mg/kg, orally) substantially suppresses the growth of MDA-MB-435 tumors. The uptake of 18F-FPPRGD2 in tumors treated with ZD4190 showed a substantial decrease from baseline on day 1 (26.74±8.12%; p<0.05), day 3 (41.19±6.63%; p<0.01), and day 1 (41.19±6.63%; p<0.01). On day seven, return to the baseline. 18F-FLT tumor uptake was likewise decreased on days 1 and 3 following the initiation of ZD4190 treatment. When compared to controls, ZD4190 did not, however, significantly change the absorption of 18F-FDG in tumors [1]. In an oral ZD4190 dose of 50 mg/kg, residual tumor growth is inhibited in a muscle model of minimal residual carcinoma [2]. ZD4190 (12.5-100 mg/kg, oral) decreases K(trans) in PC-3 prostate cancers in a dose-dependent manner. ZD4190 decreased K(trans) in PC-3 tumors by 31% after two doses and by 53% after eight doses at a dose of 100 mg/kg [3].
|
References |
|
Molecular Formula |
C19H16BRFN6O2
|
---|---|
Molecular Weight |
459.2717
|
Exact Mass |
458.05
|
CAS # |
413599-62-9
|
PubChem CID |
5329032
|
Appearance |
White to off-white solid powder
|
Density |
1.6±0.1 g/cm3
|
Boiling Point |
583.2±60.0 °C at 760 mmHg
|
Flash Point |
306.5±32.9 °C
|
Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
Index of Refraction |
1.688
|
LogP |
4.16
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
8
|
Rotatable Bond Count |
7
|
Heavy Atom Count |
29
|
Complexity |
523
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
YBTGTVGEKMZEQX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)
|
Chemical Name |
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~45.35 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1774 mL | 10.8868 mL | 21.7737 mL | |
5 mM | 0.4355 mL | 2.1774 mL | 4.3547 mL | |
10 mM | 0.2177 mL | 1.0887 mL | 2.1774 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.